ACHC vs. PCVX, ELAN, ENSG, XRAY, HQY, CYTK, EXEL, JAZZ, GMED, and IONS
Should you be buying Acadia Healthcare stock or one of its competitors? The main competitors of Acadia Healthcare include Vaxcyte (PCVX), Elanco Animal Health (ELAN), The Ensign Group (ENSG), DENTSPLY SIRONA (XRAY), HealthEquity (HQY), Cytokinetics (CYTK), Exelixis (EXEL), Jazz Pharmaceuticals (JAZZ), Globus Medical (GMED), and Ionis Pharmaceuticals (IONS). These companies are all part of the "medical" sector.
Acadia Healthcare (NASDAQ:ACHC) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, community ranking, profitability, valuation, institutional ownership and risk.
Acadia Healthcare currently has a consensus price target of $92.00, suggesting a potential upside of 23.42%. Vaxcyte has a consensus price target of $78.50, suggesting a potential upside of 27.35%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Acadia Healthcare.
Acadia Healthcare has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.
96.8% of Vaxcyte shares are held by institutional investors. 2.0% of Acadia Healthcare shares are held by insiders. Comparatively, 3.6% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Acadia Healthcare has higher revenue and earnings than Vaxcyte. Acadia Healthcare is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.
Acadia Healthcare received 521 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 67.39% of users gave Vaxcyte an outperform vote while only 66.83% of users gave Acadia Healthcare an outperform vote.
Vaxcyte has a net margin of 0.00% compared to Acadia Healthcare's net margin of -0.74%. Acadia Healthcare's return on equity of 11.21% beat Vaxcyte's return on equity.
In the previous week, Vaxcyte had 1 more articles in the media than Acadia Healthcare. MarketBeat recorded 11 mentions for Vaxcyte and 10 mentions for Acadia Healthcare. Vaxcyte's average media sentiment score of 0.81 beat Acadia Healthcare's score of 0.72 indicating that Vaxcyte is being referred to more favorably in the news media.
Summary
Vaxcyte beats Acadia Healthcare on 9 of the 17 factors compared between the two stocks.
Get Acadia Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acadia Healthcare Competitors List
Related Companies and Tools
